Published on : Oct 18, 2018
Albany, New York, October 18, 2018: Biosimilars are gaining major application in the healthcare sector owing to their advanced benefits and cost-effectiveness compared to the other biologics. Although biologics represent the fastest growing segments of cancer treatment and are recommended for treating cancer as a part of the supportive care that helps in treating side effects of the disease, rising cost of cancer treatments are leading to opt for lower cost solutions and budget-friendly treatments.
As biosimilars have no clinically relevant differences compared to the approved biologic drugs and that they focus on achieving similar results, they are gaining major significance in the healthcare sector. A comprehensive report titled as “Biosimilars in Oncology”, examines the use of biosimilars in treating cancer and significantly showcases its effectiveness as it helps reduce the side effects that patients undergo while being treated for cancer.
Biosimilars to received FDA approvals for their use in Oncology
FDA approval stands to be the most important milestone when it comes to the application of drugs across the globe. Being equally effective and providing cost-savings biosimilars are being used predominantly in the healthcare sector. Adding to this, the recent FDA approvals are fueling the use of biosimilars for the treatment of cancer. A recent approval was received by CT-P10 by Teva Pharmaceuticals industry, which is a monoclonal anti-body biosimilar to Rituxan or rituximab for treating various forms of cancer. Being the first biosimilar generic version of Rituxan, this approval is expected to open new doors of opportunities for the biosimilars in oncology. Similarly, FDA also approved Pfizer’s Talazoparib for the treatment of breast cancer.
The two emerging markets that are significant in the landscape of oncology biosimilars include India, being the nation with the most approved biosimilars and South Korea, where major biosimilar developer Celltrion is situated.
The research report discusses about the use of biosimilars in oncology, providing the assessment of the current landscape of oncology biosimilars in major markets. The report guides the reader with the inclusion of current and foreseen use of biosimilars, potential of the market, regulatory pathways, and overview of the leading and emerging biosimilar developers. The inclusion of important indications and insights regarding biosimilars in oncology allow the report readers to understand the global presence application of biosimilars in oncology.
The inclusion of information related to the availability of oncology biosimilars pertaining to current market and the pattern in use of the oncology biosimilars allows the readers to gain an understanding about the offerings of biosimilars in oncology. The report effectively analyzes the data to provide insights related to the future use of biosimilars, prescription patterns, and market dynamics to understand the scope of biosimilars.
Scrutinizing the Major Player with Competitive Analysis
With the segregated understanding of major as well as emerging players that are involved in developing biosimilars, the report highlights the key contributors of oncology biosimilars. The major players including Celltrion, Sandoz, Amgen, Bioson, and Mylan as well as the emerging players such as Boehringer and Pfizer are discussed in the research report.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1918212
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org